Short-Chain Fatty Acids Ameliorate Diabetic Nephropathy via GPR43-Mediated Inhibition of Oxidative Stress and NF-κ B Signaling
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Diabetic nephropathy (DN) is a chronic low-grade inflammatory disease. Oxidative stress and nuclear factor kappa B (NF-κ B) signaling play an important role in the pathogenesis of DN. Short-chain fatty acids (SCFAs) produced from carbohydrate fermentation in the gastrointestinal tract exert positive regulatory effects on inflammation and kidney injuries. However, it is unclear whether SCFAs can prevent and ameliorate DN. In the present study, we evaluated the role and mechanism of the three main SCFAs (acetate, propionate, and butyrate) in high-fat diet (HFD) and streptozotocin- (STZ-) induced type2 diabetes (T2D) and DN mouse models and in high glucose-induced mouse glomerular mesangial cells (GMCs), to explore novel therapeutic strategies and molecular targets for DN. We found that exogenous SCFAs, especially butyrate, improved hyperglycemia and insulin resistance; prevented the formation of proteinuria and an increase in serum creatinine, urea nitrogen, and cystatin C; inhibited mesangial matrix accumulation and renal fibrosis; and blocked NF-κ B activation in mice. SCFAs also inhibited high glucose-induced oxidative stress and NF-κ B activation and enhanced the interaction between β-arrestin-2 and I-κ B α in GMCs. Specifically, the beneficial effects of SCFAs were significantly facilitated by the overexpression GPR43 or imitated by a GPR43 agonist but were inhibited by siRNA-GPR43 in GMCs. These results support the conclusion that SCFAs, especially butyrate, partially improve T2D-induced kidney injury via GPR43-mediated inhibition of oxidative stress and NF-κ B signaling, suggesting SCFAs may be potential therapeutic agents in the prevention and treatment of DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Probiotic species in the modulation of gut microbiota: An overview
Azad, M. A. K., Sarker, M., Li, T., & Yin, J. (2018) · BioMed Research International · doi:10.1155/2018/9478630 · Cited by 803
The role of short chain fatty acids in appetite regulation and energy homeostasis
Byrne, C. S., Chambers, E. S., Morrison, D. J., & Frost, G. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.84 · Cited by 707
Lu, Y., Fan, C., Li, P., Lu, Y., Chang, X., & Qi, K. (2016) · Scientific Reports · doi:10.1038/srep37589 · Cited by 638
Kieffer, D. A., Piccolo, B. D., Vaziri, N. D., Liu, S., Lau, W. L., Khazaeli, M., Nazertehrani, S., Moore, M. E., Marco, M. L., Martin, R. J., et al. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00513.2015 · Cited by 308
The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models
Mizuno, M., Noto, D., Kaga, N., Chiba, A., & Miyake, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173032 · Cited by 230
Spiljar, M., Merkler, D., & Trajkovski, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01353 · Cited by 219
The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes
Aydin, Ö., Nieuwdorp, M., & Gerdes, V. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1020-6 · Cited by 124 · cited 1×
“Discussion SCFAs were identified as a link between gut microbiota and T2D: a number of studies in the last decade have shown that increased intake of dietary fiber and dietary supplementation with butyrate prevented or treated diet-induced weight gain, insulin resistance, and its related metabolic comorbidities [17, 1…”
Background
Cited by
Short-chain fatty acids in diseases
Zhang, D., Jian, Y.-P., Zhang, Y.-N., Li, Y., Gu, L.-T., Sun, H.-H., Liu, M.-D., Zhou, H.-L., Wang, Y.-S., & Xu, Z.-X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01219-9 · Cited by 718
Role of the gut microbiota in type 2 diabetes and related diseases
Yang, G., Wei, J., Liu, P., Zhang, Q., Tian, Y., Hou, G., Meng, L., Xin, Y., & Jiang, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154712 · Cited by 418
Health Benefits of Resistant Starch: A Review of the Literature
Bojarczuk, A., Skąpska, S., Mousavi Khaneghah, A., & Marszałek, K. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105094 · Cited by 372
Regulatory role of short-chain fatty acids in inflammatory bowel disease
Zhang, Z., Zhang, H., Chen, T., Shi, L., Wang, D., & Tang, D. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00869-5 · Cited by 259
Liu, J., Jin, Y., Ye, Y., Tang, Y., Dai, S., Li, M., Zhao, G., Hong, G., & Lu, Z.-Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626894 · Cited by 66
Metadata
- Authors
- Huang, W., Man, Y., Gao, C., Zhou, L., Gu, J., Xu, H., Wan, Q., Long, Y., Chai, L., Xu, Y., & Xu, Y.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2020-08-03
- Volume
- 2020
- Pages
- 1-21
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W3046795374
- Cited by
- 197
- References
- 7
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short-Chain Fatty Acids Ameliorate Diabetic Nephropathy via GPR43-Mediated Inhibition of Oxidative Stress and NF-κ B Signaling. https://app.cochat.ai/papers/10.1155/2020/4074832
- The paper
- Huang, W., Man, Y., Gao, C., Zhou, L., Gu, J., Xu, H., Wan, Q., Long, Y., Chai, L., Xu, Y., & Xu, Y. (2020). Short-Chain Fatty Acids Ameliorate Diabetic Nephropathy via GPR43-Mediated Inhibition of Oxidative Stress and NF-κ B Signaling. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2020/4074832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.